Kathryn E Hitchcock, Eric D Miller, Qian Shi, Jesse G Dixon, Sepideh Gholami, Sarah B White, Christina Wu, Christopher C Goulet, Manju George, Kyung-Wook Jee, Chadwick L Wright, Rona Yaeger, Ardaman Shergill, Theodore S Hong, Thomas J George, Eileen M O'Reilly, Jeffrey A Meyerhardt, Paul B Romesser
Background: For patients with liver-confined metastatic colorectal cancer (mCRC), local therapy of isolated metastases has been associated with long-term progression-free and overall survival (OS). However, for patients with more advanced mCRC, including those with extrahepatic disease, the efficacy of local therapy is less clear although increasingly being used in clinical practice. Prospective studies to clarify the role of metastatic-directed therapies in patients with mCRC are needed. Methods: The Evaluating Radiation, Ablation, and Surgery (ERASur) A022101/NRG-GI009 trial is a randomized, National Cancer Institute-sponsored phase III study evaluating if the addition of metastatic-directed therapy to standard of care systemic therapy improves OS in patients with newly diagnosed limited mCRC...
December 23, 2023: Research Square